Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.
about
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaStem cell transplantation for neuroblastomaNeuroblastoma: issues in transplantationPharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UseA phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism.Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma.Immunotherapy for pediatric cancer.Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology GroupPilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: a report of the children's oncology group (COG)Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma.Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing lossPilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyOutcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma.Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.Advances in Risk Classification and Treatment Strategies for Neuroblastoma.The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis.A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1A comparative study of intratumoral chemotherapy in advanced childhood common solid tumors.Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group.Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34.Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors.Development of treatment strategies for advanced neuroblastoma.Probenecid Sensitizes Neuroblastoma Cancer Stem Cells to Cisplatin.Advances in emerging drugs for the treatment of neuroblastoma.Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.Granulocyte colony stimulating factor alters the phenotype of neuroblastoma cells: implications for disease-free survival of high-risk patients.Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience.Long-term results of high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma patients: a report of the Spanish working party for BMT in children (Getmon).Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results.Recent advances in neuroblastoma
P2860
Q24186636-D55DD878-597D-417B-B57F-8779FC4ECD39Q24200296-4CE65147-036B-4527-94D3-BEDBAB72E8D2Q24629221-20B94D83-B968-4899-8103-A7C6C8C13CE2Q27008197-7C18F225-D719-44DE-9CB9-E054A1C5095DQ28068930-F836C9C6-314C-426E-AB21-0155BE45F74FQ33332916-F08AF382-B628-4838-B905-B122CA8F1A90Q33373879-2EAB157F-47A6-4925-94E1-AB546209CEB0Q33703811-02DAAEF9-1F03-4C00-AA4A-9A14DEEBEFA1Q33788210-6E7B5D58-14A1-4F1D-91E4-C77A7B223545Q33924586-CE12722A-D976-4F76-A8B3-863FC8215299Q33999779-58E17A40-1C8F-4747-8189-AA84264174EFQ34999814-2832E075-A280-4CE0-8C3C-F1AD17B4B40DQ35082400-8DB931BD-A113-43F3-8E84-60AAD0A9BB28Q35102499-D701CAD5-4202-43A1-993F-A776668C0CEAQ35172741-75BA7E5F-E1D2-4742-854C-E1E0D512A1BCQ35565630-01D5342B-E958-45F7-AD18-DA3833DCCC90Q35589086-75267239-6ACF-445C-BA5F-A522DE2E1BE5Q35887473-DFC3F97F-795E-48AE-ABF3-C3CE13812013Q36022690-E705A526-661C-4A6B-BD51-CC033A808AD8Q36053801-E80BA546-64A9-4A0F-AD7B-A61B1C61553AQ36692408-DD52DBDD-9EA2-4143-93D5-F0DCBD8FE24BQ36800194-32B0FA63-608D-4746-82AB-20F5B6B4E8ABQ37291129-7749BAFC-E5BE-4947-A252-C9C1D0506E6CQ37480824-FCCF3BD2-82E3-4C85-B622-B8811E7F045DQ37570413-05AFA680-1536-4E07-A752-F7ACBE376191Q37580472-57ACDCA1-B672-47F2-BDC0-657D2C07FEC4Q37716119-11F85413-34B1-465F-BCAA-DA341028E986Q38010377-6B84CF0E-8428-4B67-8838-8F96EB89B493Q38787387-ABE66CA7-7FE7-4FD1-9BFA-2E5FA15A8C60Q39158415-4D03F911-240C-4A2C-9D50-8030029F555EQ39655015-743DD4F7-1387-4B5A-85C5-1F78364C157DQ39981228-420C8BBC-D9E6-4F19-98BF-649A237C2793Q42721713-6B36332C-C184-4883-8471-DC69D2247C1AQ43680012-9C97D46C-A81F-4C9A-8982-2AD91BDCE8FCQ44098566-F82CEED7-E172-41DF-932D-68338B49FA22Q44128427-880EBD3C-615E-4FDA-9FE6-08AC2E1B14F0Q53319588-668161A6-14C7-4947-83E8-C8B5729FD65BQ56637924-734E1F70-941E-4D64-98B8-AD9ABD0B2B64
P2860
Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotherapy dose intensity co ...... l in metastatic neuroblastoma.
@en
Chemotherapy dose intensity co ...... l in metastatic neuroblastoma.
@nl
type
label
Chemotherapy dose intensity co ...... l in metastatic neuroblastoma.
@en
Chemotherapy dose intensity co ...... l in metastatic neuroblastoma.
@nl
prefLabel
Chemotherapy dose intensity co ...... l in metastatic neuroblastoma.
@en
Chemotherapy dose intensity co ...... l in metastatic neuroblastoma.
@nl
P1476
Chemotherapy dose intensity co ...... l in metastatic neuroblastoma.
@en
P2093
P304
P356
10.1200/JCO.1991.9.6.1050
P407
P577
1991-06-01T00:00:00Z